Nasdaq stocks posting largest volume increases
AP - Fri Aug 08, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage increases
AP - Fri Aug 08, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Fri Aug 08, 5:06PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Gap and Post Holdings are big market movers
AP - Fri Aug 08, 3:36PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
IIROC Trade Resumption - TKM
CNW Group - Fri Aug 08, 7:13AM CDT
Trading resumes in:
Tekmira Conference Call and Webcast Advisory: Corporate Update and Second Quarter Financial Results
GlobeNewswire - Thu Aug 07, 7:36PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it will hold a conference call and webcast on Wednesday, August 13, 2014 at 2 p.m. Pacific Time (5 p.m. Eastern Time) to provide a corporate update and report financial results for the second quarter ended June 30, 2014.
FDA lifts hold on experimental Ebola drug
By MATTHEW PERRONE - AP - Thu Aug 07, 6:26PM CDT
WASHINGTON (AP) — U.S. health authorities have eased safety restrictions on an experimental drug to treat Ebola, a move that could clear the way for its use in patients infected with the deadly virus.
FDA Modifies Tekmira's TKM-Ebola Clinical Hold to Partial Hold
GlobeNewswire - Thu Aug 07, 3:45PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that the U.S. Food & Drug Administration (FDA) has verbally confirmed they have modified the full clinical hold placed on the TKM-Ebola Investigational New Drug Application (IND) to a partial clinical hold. This action enables the potential use of TKM-Ebola in individuals infected with Ebola virus.
IIROC Trading Halt - TKM
CNW Group - Thu Aug 07, 3:21PM CDT
The following issues have been halted by IIROC:
Tekmira Provides Update on TKM-Ebola Phase I Clinical Hold
GlobeNewswire - Mon Jul 21, 11:19AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced an update on the TKM-Ebola Phase I clinical hold. The Company has received the clinical hold letter from the U.S. Food and Drug Administration (FDA) and is preparing a Complete Response to the Agency. The Company anticipates this matter will be resolved by Q4, 2014.
Tekmira Receives $1.5 Million Milestone Payment
GlobeNewswire - Wed Jul 09, 6:00PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has received a $1.5 million milestone payment from Monsanto following completion of specified program developments. The development milestone is part of the research program under the Option Agreement Tekmira signed with the agriculture company, which we announced on January 13, 2014. The Option Agreement relates to Tekmira's proprietary delivery technology and intellectual property for use in agricultural applications. The potential value of the transaction could reach up to $86.2 million, following the successful completion of all program milestones.